Harvard Bioscience (HBIO) Raw Materials (2011 - 2026)

Harvard Bioscience (HBIO) has 16 years of Raw Materials data on file, last reported at $13.3 million in Q1 2026.

• Raw Materials for Q1 2026 came in at $13.3 million, down 9.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.3 million (down 9.09% YoY), and the FY2025 annual result was $12.2 million, down 20.28% from the prior year.
• Raw Materials improved to $13.3 million in Q1 2026 per HBIO's latest filing, from $12.2 million in the prior quarter.
• Over five years, Raw Materials peaked at $19.2 million in Q2 2022 and troughed at $12.2 million in Q4 2025.
• A 5-year average of $15.9 million and a median of $15.4 million in 2023 frame the typical range for Raw Materials.
• The sharpest annual moves came in 2022 and 2025: Raw Materials surged 31.79% in 2022, then fell 24.1% in 2025.
• A 5-year view of Raw Materials shows it stood at $17.4 million in 2022, then fell by 11.65% to $15.4 million in 2023, then slipped by 0.9% to $15.3 million in 2024, then fell by 20.28% to $12.2 million in 2025, then grew by 9.58% to $13.3 million in 2026.
• Business Quant data shows HBIO's Raw Materials at $13.3 million in Q1 2026, $12.2 million in Q4 2025, and $13.5 million in Q3 2025.